Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZYKR1
- Development stage
- Unknown
- Lead developer
- Zydus Pharma
01
Overview
ZYKR1: sourced facts only. name: "ZYKR1 showed KOR agonistic activity in the cAMP assay, with an EC50 of 0.061 nM and more than 105-fold selectivity over the mu and delta opioid receptors (EC50 > 10 μM)." [PMID:35443192]; target: "ZYKR1 showed KOR agonistic activity in the cAMP assay, with an EC50 of 0.061 nM and more than 105-fold selectivity over the mu and delta opioid receptors (EC50 > 10 μM)." [PMID:35443192]; developer: "Department of Pharmacology, Cadila Healthcare Ltd., Sarkhej-Bavla N.H. No. 8A, Moraiya, Ahmedabad, 382 213, Gujarat, India. Electronic address: [email protected]." [PMID:35443192]; stage: "In conclusion, ZYKR1 has potent antinociceptive action in visceral pain and pruritus with limited CNS side effects in preclinical models owing to its peripheral restriction." [PMID:35443192]
02
Targets
KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on ZYKR1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZYKR1.